ABBV
AbbVie just brought the IBD receipts
AbbVie used the American College of Gastroenterology’s 2026 annual meeting to show off 22 scientific abstracts from its inflammatory bowel disease portfolio. Translation: the company rolled up with a stack of data and a very clear message — its gut meds are still doing the heavy lifting.
The headline grabber was new Phase 3 AFFIRM data for SKYRIZI, which showed higher rates of clinical and endoscopic response in Crohn’s disease patients versus placebo across the efficacy endpoints the company highlighted. In pharma-speak, that’s the kind of evidence that keeps a therapy in the “do not ignore” bucket.
SKYRIZI keeps building the case
AbbVie also shared open-label extension analyses suggesting SKYRIZI’s endoscopic benefits held up over time, even among patients with more complex disease histories and prior treatment exposure. That matters because Crohn’s isn’t exactly a polite, one-size-fits-all illness — the harder-to-treat patients are often where a drug either earns its stripes or gets politely shown the door.
RINVOQ gets its own spotlight
Then there’s RINVOQ, which showed disease control in real-world studies of patients with advanced Crohn’s disease. That’s not the same as a shiny controlled trial, but it does matter: real-world data is the pharma equivalent of “okay, but does it work when the lab coat comes off?”
For AbbVie, the bigger story is the same old one that keeps showing up in the company’s playbook: make immunology look less like a patent cliff and more like a fortress. If SKYRIZI and RINVOQ keep stacking evidence, that franchise stays a lot harder to mess with.
Big picture: this isn’t a moonshot headline, but it is the kind of steady, positive clinical support that helps a giant drugmaker defend its cash flow and keep investors from worrying about what comes after the blockbuster parade ends.